Seaport Therapeutics
Focus: Seaport Therapeutics is a Boston-based biotech company leveraging a neuro discovery platform to develop therapeutics in psychiatry and metabolic diseases. The company operates as a pre-revenue biotech with a focused pipeline in early-to-mid stage development.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Open Jobs
6
Should You Work at Seaport Therapeutics?
AI assessmentSeaport represents a high-risk, high-reward early-stage bet best suited for scientists seeking deep platform ownership, not career stability.
Why Work Here
- Opportunity to contribute to psychiatry and metabolic disease space with differentiated neuro platform technology
- Early-stage company offers high leverage and potential equity upside with fresh funding trajectory
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_2
Clinical Trials (1)
NCT07065240A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Phase 2Help build intelligence for Seaport Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.